The opioid epidemic has captivated the country for a decade, although lost attention during 2020 in the face of the COVID-19 pandemic. While the human toll of the opioid epidemic is being addressed differently across the country, efforts in managing prescription opioids and in supporting medication-assisted treatment are showing measurable progress in many states.

This webinar will include key findings from a recent report released by the IQVIA Institute for Human Data Science – Prescription Opioid Trends in the United States: Measuring and understanding progress in the opioid crisis. It will also include an update from IQVIA's U.S. Regulatory Compliance team on the Drug Enforcement Administration's (DEA's) long-awaited proposed suspicious order monitoring rule, as well as an examination of DEA opioid quota trends for recent years.

KEY SPEAKERS

Michael Kleinrock
Research Director, IQVIA Institute for Human Data Science

Mark Caverly
Senior Consultant, IQVIA U.S. Regulatory Compliance

Paul Hamby
Group Director, IQVIA U.S. Regulatory Compliance